Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD)
· seekingalpha.com
Ironwood Pharmaceuticals is rated a Buy after a 14.5% decline driven by the CFO's resignation and insider selling. Read more on IRWD stock here.
Small- to mid-cap pharma stocks offer distinctive opportunities for contrarian investors able to look beyond short-term volatility and identify undervalued stoc...